Prior research has indicated that the onset of endocrinopathies occurs within a timeframe of 9 to 12 weeks following the administration of CTLA-4 and within an interval of 4 to 18 weeks following the administration of anti-PD-1 [20,21]. The gene discussed is CTLA4; the disease is endocrine system disorder.